PPH:NSD-VanEck Vectors Pharmaceutical ETF

ETF | Health | NASDAQ Global Market

Last Closing Price

USD 62.76

Change

-0.10 (-0.16)%

Market Cap

USD 0.30B

Volume

0.11M

Yahoo Analyst Target

N/A

STA Analyst Target

N/A
Yahoo Analyst Rating

N/A

STA Analyst Rating

N/A

STA Verdict

Verdict

About

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Inception Date: 20/12/2011

Primary Benchmark: MVIS US Listed Pharmaceutical 25 NR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.41%

Management Expense Ratio: 0.35 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Nasdaq Biotechnology I.. 0.47 %

-1.38 (-1.23%)

USD 10.25B
BBH VanEck Vectors Biotech ETF 0.35 %

-0.55 (-0.43%)

USD 0.63B
PSCH PowerShares S&P SmallCap Healt.. 0.29 %

-0.55 (-0.52%)

USD 0.30B
PTH PowerShares DWA Healthcare Mom.. 0.60 %

-1.06 (-1.40%)

USD 0.14B
GNRX Market Vectors Generic Drugs E.. 0.55 %

-0.14 (-0.54%)

USD 3.94M
SLIM The Obesity ETF 0.50 %

-0.11 (-0.34%)

USD 3.23M
BFIT Global X Health & Wellness The.. 0.68 %

N/A

N/A
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

-0.67 (-2.62%)

N/A
LNGR Global X Longevity Thematic ET.. 0.68 %

+0.07 (+0.35%)

N/A

ETFs Containing PPH

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health)
Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.82% 80% B- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.82% 80% B- 73% C
Trailing 12 Months  
Capital Gain 18.48% 40% F 61% D-
Dividend Return 2.15% 100% A+ 53% F
Total Return 20.63% 50% F 61% D-
Trailing 5 Years  
Capital Gain 50.97% 20% F 46% F
Dividend Return 13.97% 100% A+ 53% F
Total Return 64.95% 20% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 6.18% 40% F 45% F
Dividend Return 8.23% 50% F 47% F
Total Return 2.05% 100% A+ 53% F
Risk Return Profile  
Volatility (Standard Deviation) 18.18% 40% F 70% C-
Risk Adjusted Return 45.28% 30% F 52% F
Market Capitalization 0.25B 57% F 46% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.